Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?
作者信息
Grover Madhusudan, Camilleri Michael
机构信息
Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota.
出版信息
Clin Gastroenterol Hepatol. 2014 Jun;12(6):960-2. doi: 10.1016/j.cgh.2013.12.025. Epub 2014 Jan 3.
Abstract
摘要
相似文献
1
Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?
Clin Gastroenterol Hepatol. 2014 Jun;12(6):960-2. doi: 10.1016/j.cgh.2013.12.025. Epub 2014 Jan 3.
2
Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
Clin Gastroenterol Hepatol. 2014 Jun;12(6):953-9.e4. doi: 10.1016/j.cgh.2013.11.024. Epub 2013 Dec 4.
3
Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
Gastroenterology. 2016 Feb;150(2):358-66.e8. doi: 10.1053/j.gastro.2015.10.047. Epub 2015 Nov 6.
4
Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
BMC Gastroenterol. 2018 Jan 8;18(1):5. doi: 10.1186/s12876-017-0734-2.
5
Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
Neurogastroenterol Motil. 2011 Dec;23(12):1098-104. doi: 10.1111/j.1365-2982.2011.01771.x. Epub 2011 Sep 15.
6
Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.
J Gastroenterol. 2016 Sep;51(9):874-82. doi: 10.1007/s00535-016-1165-5. Epub 2016 Jan 22.
7
Eluxadoline approved for irritable bowel syndrome with diarrhea.
Am J Health Syst Pharm. 2015 Jul 1;72(13):1078. doi: 10.2146/news150043.
8
Advancements in drug development for diarrhea-predominant irritable bowel syndrome.
Expert Opin Investig Drugs. 2018 Mar;27(3):251-263. doi: 10.1080/13543784.2018.1442434. Epub 2018 Feb 22.
9
Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea.
Med Lett Drugs Ther. 2016 Jan 4;58(1485):4-5.
10
[Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea].
Nihon Yakurigaku Zasshi. 2009 May;133(5):281-91. doi: 10.1254/fpj.133.281.
引用本文的文献
1
Exploring the Antidiarrheal Properties of Papaya Leaf: Insights Study in Mice-Model and Analysis at M3 Muscarinic Acetylcholine Receptor Interaction.
Scientifica (Cairo). 2024 Jun 12;2024:1558620. doi: 10.1155/2024/1558620. eCollection 2024.
2
Evaluation of the gastrointestinal anti-motility effect of stem bark extract: A mechanistic study of antidiarrheal activity.
J Pharm Anal. 2021 Dec;11(6):776-782. doi: 10.1016/j.jpha.2020.06.009. Epub 2020 Jul 21.
3
5-HT receptor signaling in serotonin transporter-knockout rats: a female sex-specific animal model of visceral hypersensitivity.
Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G132-G143. doi: 10.1152/ajpgi.00131.2018. Epub 2018 Oct 25.
4
Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.
PLoS One. 2017 Mar 14;12(3):e0172846. doi: 10.1371/journal.pone.0172846. eCollection 2017.
5
Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.
J Gastroenterol. 2016 Sep;51(9):874-82. doi: 10.1007/s00535-016-1165-5. Epub 2016 Jan 22.
6
Pharmacologic Agents for Chronic Diarrhea.
Intest Res. 2015 Oct;13(4):306-12. doi: 10.5217/ir.2015.13.4.306. Epub 2015 Oct 15.
7
Novel therapeutic agents in neurogastroenterology: advances in the past year.
Neurogastroenterol Motil. 2014 Aug;26(8):1070-8. doi: 10.1111/nmo.12386. Epub 2014 Jun 23.
本文引用的文献
1
Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
Clin Gastroenterol Hepatol. 2014 Jun;12(6):953-9.e4. doi: 10.1016/j.cgh.2013.11.024. Epub 2013 Dec 4.
2
A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.
Therap Adv Gastroenterol. 2013 Sep;6(5):344-57. doi: 10.1177/1756283X13491798.
3
Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome.
Clin Exp Gastroenterol. 2013 Jul 25;6:123-8. doi: 10.2147/CEG.S32721. Print 2013.
4
Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome.
Expert Opin Pharmacother. 2013 Jun;14(9):1151-60. doi: 10.1517/14656566.2013.794223. Epub 2013 Apr 27.
5
Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.
Aliment Pharmacol Ther. 2012 Sep;36(5):437-48. doi: 10.1111/j.1365-2036.2012.05208.x. Epub 2012 Jul 10.
6
The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.
Drug Saf. 2011 Jul 1;34(7):545-65. doi: 10.2165/11590690-000000000-00000.
7
Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats.
Br J Pharmacol. 2009 Nov;158(5):1210-26. doi: 10.1111/j.1476-5381.2009.00392.x. Epub 2009 Sep 25.
8
Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844. doi: 10.1038/ajg.2009.223. Epub 2009 May 26.
9
A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.
Digestion. 2008;77(3-4):225-35. doi: 10.1159/000150632. Epub 2008 Jun 10.
10
Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
Clin Gastroenterol Hepatol. 2008 May;6(5):545-55. doi: 10.1016/j.cgh.2007.12.015. Epub 2008 Jan 31.
Zotero 插件